07 Jan 2022
The National Institute for Health and Care Excellence (NICE) has rejected olaparib as a routine treatment for hormone-relapsed metastatic prostate cancer, due to high costs.
Migraines and menopause symptoms linked to cardiovascular disease risk
19 Apr 2024
Risk of postpartum depression associated with stress during adolescence
19 Apr 2024
Surgery for hypoparathyroidism sees reduced facture rates
19 Apr 2024
Patients with type 2 diabetes taking antidepressants have a higher mortality risk
19 Apr 2024